AKT1 and acute myeloblastic leukemia with maturation: Thus, a potential therapeutic strategy for interfering with the development and progression of AM involves inhibiting miR-21 expression to suppress the activation of PI3K/AKT/mTOR, thereby modulating the balance between proliferation and apoptosis.